CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Sitagliptin phosphate

Last Updated: October 29, 2009
Result type: Reports
Project Number: SR0181-000
Product Line: Reimbursement Review

Generic Name: Sitagliptin phosphate

Brand Name: Januvia

Manufacturer: Merck Frosst Canada Ltd.

Therapeutic Area: Diabetes mellitus (Type 2)

Indications: Diabetes mellitus (Type 2)

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: June 23, 2010

Recommendation Type: List with clinical criteria and/or conditions